GLENDA WILBURN: Open Payments
NPI 1861650574 · ORANGE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,581 in 78 payments from 15 companies in 2025. Trend: 2023 $1,528 · 2024 $1,272 · 2025 $1,581
Food & beverage: $1,581
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $333 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $199 |
| AstraZeneca Pharmaceuticals LP | 2 | $192 |
| Sumitomo Pharma America, Inc. | 6 | $151 |
| Axsome Therapeutics, Inc. | 8 | $147 |
| PFIZER INC. | 7 | $131 |
| Lilly USA, LLC | 6 | $116 |
| Astellas Pharma US Inc | 5 | $89 |
| GlaxoSmithKline, LLC. | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 3 | $51 |
Products named: Kerendia, BREZTRI, GEMTESA, Auvelity, QULIPTA, MOUNJARO, ELIQUIS, VRAYLAR.
Industry payments across TX — which companies pay providers there.
